ZTA-261 , CAS No.3049368-51-3

CAS: 3049368-51-3 Cat. No.: Z1455501 Formula: C₂₁H₁₄F₆O₃ Peso molecolare: 428.32

Storage

Store at -20°C

Shipped In

Ice chest + Ice pads

Panoramica

ZTA-261 is a highly selective and low toxic thyroid hormone receptor β subtype ( THR-β ) agonist ( IC 50 =6.3 nM) that reduces body weight and visceral fat through a liothyronine mediated pathway. ZTA-261 can be used in the study of lipid metabolism and obesity prevalence.

Specifiche

Condizioni di conservazione di stoccaggio

Store at -20°C

Spedito in

Ice chest + Ice pads

Questo prodotto richiede spedizione a catena fredda. I servizi di terra e altri servizi economici non sono disponibili.

Nomi e identificatori

Peso molecolare

428.32

Application Protocols

No tested application protocols are provided for this item. The following outlines general, non-item-specific procedures for handling small-molecule library compounds.

• Stock preparation (general)
  • Warm DMSO to room temperature, weigh compound quickly to minimize moisture uptake, and prepare 10–50 mM stocks. Mix until fully dissolved; brief sonication may help.
  • Sterile-filter through 0.22 µm PTFE only if required and if the compound is known to be stable/soluble; otherwise maintain aseptic technique during handling.
• Assay dosing (general)
  • Dilute stocks into assay buffer/media to the desired concentration, keeping final DMSO ≤0.5–1% v/v. Include matched vehicle controls.
  • Confirm absence of precipitation visually or by nephelometry; if precipitation occurs, increase dilution steps or adjust solvent system within assay tolerance.
• Documentation
  • Record lot number, weighing records, stock concentration, dilution scheme, and storage conditions for reproducibility.

For item-specific protocols (e.g., target assays or recommended concentrations), request the technical data sheet.

Biological Roles

No biological mechanism, target class, or pathway annotation is provided for this item. As such, only general guidance for handling small-molecule library members is offered below.

• Item-specific biological information
  • Target/Mechanism: Not specified for this item; refer to product dossier or literature.
  • Selectivity profile: Not specified for this item; refer to CoA/Spec Sheet.
• General considerations for small-molecule probes (non-clinical)
  • Validate on-target activity using orthogonal assays (biochemical vs. cellular) and counter-screens to exclude interference (fluorescence, redox cycling, aggregation).
  • Map preliminary structure–property relationships (SPR/SAR) if analogs are available to improve potency, solubility, and selectivity.
  • Assess cell permeability and metabolic stability (microsomes, S9) if cellular activity is a goal.
  • Avoid biological claims until dose–response, time-dependence, and toxicity (e.g., ATP content assays) are quantified.

For curated target data, please request the full data sheet or screening panel results. All uses are for research only.

Buffer Applications

This product is not a buffering agent and is not typically used to formulate buffer systems.

• Item-specific note
  • No buffer-related specifications or pKa values are provided for this item.
• Practical guidance (general)
  • When dosing this compound into biological buffers, maintain final DMSO ≤0.5–1% v/v to preserve assay integrity.
  • Common assay buffers include PBS (pH ~7.4), HEPES (pH 7.2–7.5), and Tris (pH 7.5–8.0); select based on target biology and compound stability.
  • To mitigate precipitation, pre-dilute the DMSO stock in buffer stepwise (e.g., 1:100 then to final) with vigorous mixing or sonication, and confirm clarity before use.

For any buffer–compound compatibility concerns (e.g., nucleophilic or oxidative instability), consult the SDS/CoA and run a short stability-in-buffer LC–MS check.

Green Alternatives

When preparing solutions or conducting ancillary processing with this compound, solvent and process choices can improve sustainability. Since the structure is not disclosed here, the following guidance is general.

• Prefer greener diluents where compatible
  • Replace chlorinated solvents in workups with ethyl acetate or 2-MeTHF when feasible.
  • For stock solutions, DMSO remains standard for screening; consider propylene carbonate or PEG-400 for certain applications, balancing assay compatibility.
• Small comparison (general considerations)
  • DMSO: high solvency, widely compatible, relatively low hazard; not bio-based.
  • 2-MeTHF: renewable feedstock, lower peroxide tendency than THF; limited water miscibility may restrict use.
  • EtOAc/IPA: lower toxicity vs. chlorinated solvents; volatility aids recovery.
• Operational practices
  • Use microscale reactions/assays to reduce solvent volumes.
  • Employ closed containers and accurate dispensing to minimize waste and exposure.
  • Evaluate aqueous buffered systems with minimal co-solvent when biological assays permit.

Item-specific greener alternatives cannot be prescribed without structural data; verify compatibility experimentally.

Pharmaceutical Uses

No pharmacopeial status, excipient role, or formulation designation is provided for this item. The compound is supplied strictly for research use only and is not intended for human or veterinary use.

• Item-specific
  • Regulatory status: Not specified; not for clinical use.
  • Excipient/formulation role: Not specified.
• General R&D formulation practices (non-clinical)
  • For in vitro work, prepare concentrated DMSO stocks and dilute into assay media with proper vehicle controls.
  • For exploratory in vivo research (where permitted), determine vehicle compatibility (e.g., captisol, PEG-400/saline, 0.5% methylcellulose) only after confirming solubility and stability; follow institutional approvals and regulations.
  • Document lot number, purity, and salt form in all reports to ensure traceability.

Contact Aladdin Scientific for available documentation (CoA, technical note) if formulation-oriented data are required.

Physical Properties

Item-specific physical constants have not been provided in the current listing. Below is a clear separation of what is known and typical next steps.

• Item-specific (from Product Data)
  • Appearance: Not specified for this item; refer to CoA/Spec Sheet.
  • Molecular Weight: Not specified for this item; refer to CoA/Spec Sheet.
  • Molecular Formula: Not specified for this item; refer to CoA/Spec Sheet.
• Commonly requested properties (literature/computed — not available here)
  • Melting point (literature/computed): Not specified for this item; refer to CoA/Spec Sheet.
  • Boiling point (literature): Not applicable for most solid screening compounds; specific value not specified.
  • Density, refractive index: Not specified for this item; refer to CoA/Spec Sheet.
  • pKa, logP/logD, PSA: Not specified for this item; refer to CoA/Spec Sheet.
  • Solubility: Not specified for this item; refer to CoA/Spec Sheet. As a general practice, start with DMSO stock solutions (see Storage & Reconstitution).

Practical guidance (general)

• For unknown solids, evaluate solubility panels (DMSO, DMF, MeOH, EtOH, aqueous buffer with 0.5–2% DMSO, and pH-adjusted buffers) at 25 °C.
• If weakly basic, solubility can improve in mildly acidic buffer (pH 5–6); if weakly acidic, consider pH 8–9 for screening purposes. Validate chemical stability before pH adjustment.

Quality and Grades

Clarity on grade/purity is essential for screening data quality.

• Item-specific (from Product Data)
  • Grade/Purity: Not specified for this item; refer to CoA/Spec Sheet.
• How to interpret common grades (general guidance)
  • Screening/Library grade: Typically accompanied by HPLC chromatograms and LC–MS identity confirmation; purity often ≥90–95% area by HPLC (literature/market practice). UV cutoffs and trace metals are generally not specified.
  • Analytical grade (>98%) may be available upon request for SAR follow-up.
• Recommended verifications (general)
  • Request CoA (HPLC purity, LC–MS, NMR if available) and impurity profile.
  • If biological assay data are sensitive to redox or electrophiles, screen for PAINS/reactive impurities and test lot-to-lot consistency.
  • Confirm salt form/solvate and water content (KF) when solubility deviates from expectations.
• Stabilizers/additives
  • Not specified for this item; refer to CoA/Spec Sheet. If a stabilizer is present, it may influence UV/fluorescence assays; adjust controls accordingly.

Reaction and Applications

This product is listed under a small-molecule/compound library and is ordinarily used as a screening tool compound rather than as a reagent or solvent.

• Item-specific applications (from Product Data)
  • Manufacturer applications: Not specified in the listing.
• General research applications for library compounds
  • In vitro screening: biochemical assays (enzymes, receptors), cell-based phenotypic assays, and target deconvolution workflows.
  • Orthogonal confirmation: follow-up with counter-screens (aggregation controls, redox interference tests, detergent sensitivity) to ensure on-target effects.
  • SAR development: if hits emerge, procure additional lots/analogs for structure–activity relationship studies.
• Practical tips (general)
  • Prepare concentrated DMSO stocks (e.g., 10–50 mM) and store aliquots at −20 °C to minimize freeze–thaw.
  • Include vehicle controls matched to final DMSO percentage and consider solubility/precipitation checks (nephelometry or visual inspection) at assay concentration.
  • Assess chemical stability (48–72 h) under assay conditions by LC–MS to exclude time-dependent degradation.

If you need this compound for synthetic transformations or as a probe with defined target class, please request the detailed data sheet or structure.

Reaction Conditions

No item-specific reaction condition data are provided, and this compound is not listed as a reagent. Accordingly, detailed synthetic conditions are not applicable.

• Item-specific reaction data
  • Not specified for this item; refer to CoA/Spec Sheet.
• General guidance (if using as a substrate in method development)
  • Start with analytical-scale reactions (5–20 mg) to probe stability.
  • Select conditions based on functional groups once the structure is known (e.g., Pd-catalyzed cross-coupling for aryl halides, amide couplings for carboxylic acids/amines).
  • Monitor by LC–MS/HPLC and verify product identity with orthogonal methods (HRMS, NMR).

For precise protocols, structural disclosure is necessary.

Safety and Handling

Safety information specific to this item is limited in the listing; adopt conservative laboratory practices.

• Item-specific hazard data
  • Signal Word (GHS): Not specified for this item; refer to SDS.
  • H-Statements: Not specified for this item; refer to SDS.
  • GHS Classification/Pictograms: Not specified for this item; refer to SDS.
• General precautions (best practice for small molecules)
  • Wear lab coat, safety glasses, and appropriate gloves (e.g., nitrile). Handle powders in a fume hood to minimize inhalation exposure.
  • Avoid contact with skin, eyes, and clothing. Prevent dust formation and aerosolization.
  • Do not ingest or inhale. Wash thoroughly after handling.
• Storage incompatibilities (general)
  • Store tightly closed under dry, inert conditions when feasible. Keep away from oxidizers, strong acids/bases, and sources of ignition.
  • Follow item-specific storage: Store at -20°C (from Product Data). Minimize freeze–thaw.
• First-aid overview (consult SDS for authoritative instructions)
  • Inhalation: Move to fresh air; seek medical attention if symptoms persist.
  • Skin/eye contact: Rinse with water for at least 15 minutes; remove contaminated clothing; seek medical attention as needed.
  • Ingestion: Rinse mouth; do not induce vomiting; seek medical attention.
• Waste disposal
  • Dispose of as organic laboratory waste per institutional and local regulations.

Always consult the product-specific SDS for definitive hazard and response information.

Solvent Selection

Without a disclosed structure, solvent choice should follow a tiered, property-agnostic workflow suitable for small-molecule screening compounds.

• Polarity classes and miscibility (general)
  • Start with DMSO due to broad solubilizing power and assay compatibility at ≤0.5–1% v/v.
  • Secondary options: DMF, NMP, ethanol, methanol. For aqueous delivery, use co-solvent strategies (e.g., 0.2–1% DMSO + surfactant or cyclodextrin if compatible).
  • For scalable preparations or extractions, consider ethyl acetate, isopropanol, or acetonitrile depending on polarity and stability.
• Practical selection tips (general)
  • If basic functionality suspected: dissolve in DMSO, then dilute into citrate or acetate buffer (pH 5–6).
  • If acidic: DMSO stock followed by dilution into Tris or phosphate buffer (pH 8–8.5).
  • Poorly soluble neutrals: explore cosolvent blends (DMSO/PEG-400/saline) or cyclodextrin inclusion complexes.
• Comparison snapshot (general)
  • DMSO: highest success rate; minimal UV interference above 260 nm; freezing point 18.5 °C (handle warmed).
  • DMF/NMP: strong solvents but higher background in some assays; consider only if DMSO fails.
  • Alcohols: rapid evaporation, useful for film casting before reconstitution.

Item-specific solvent recommendations are not provided; verify with small-scale solubility tests.

Storage and Reconstitution

How to store and prepare this compound for research use, clearly separating item-specific requirements from general best practices.

• Item-specific (from Product Data)
  • Storage Conditions: Store at −20°C.
  • Shipped In: Ice chest + Ice pads to maintain low temperature during transit.
• General reconstitution guidance (for small-molecule solids)
  • Allow the vial to equilibrate to room temperature in a desiccator before opening to prevent moisture condensation.
  • Prepare a concentrated DMSO stock (e.g., 10–50 mM) based on intended assay range. If solubility is uncertain, start at 5–10 mM and adjust.
  • Mix thoroughly; if needed, use brief bath sonication. Avoid prolonged heating unless stability is verified.
  • Aliquot stocks into single-use vials or tubes to avoid repeated freeze–thaw cycles.
  • Store aliquots at −20°C, protected from light if the compound is light-sensitive (not specified for this item; verify on CoA/SDS).
  • For aqueous working solutions, prepare fresh on the day of use or validate short-term stability by LC–MS.
• Stability notes
  • Appearance, water content, and stability are not specified for this item; refer to CoA/Spec Sheet.
  • If precipitation occurs on dilution, increase dilution steps, adjust pH within biological tolerance, or include a minimal percentage of co-solvent (e.g., 0.2–1% DMSO).

Always consult the item’s CoA and SDS for any additional, lot-specific instructions.

Structure and Identity

Overview of identity information available for this screening compound.

• Item-specific (from Product Data)
  • SKU: Z1455501
  • Product Name: ZTA-261
  • CAS: 3049368-51-3
  • Category Path: 全部 / 可售 / 小分子和化合物库
  • Storage Conditions: Store at -20°C
  • Shipped In: Ice chest + Ice pads
  • Research Use: For research use only
• Item-specific identifiers
  • Molecular Formula: Not specified for this item; refer to CoA/Spec Sheet.
  • Molecular Weight: Not specified for this item; refer to CoA/Spec Sheet.
  • SMILES: Not specified for this item; refer to CoA/Spec Sheet.
  • InChIKey: Not specified for this item; refer to CoA/Spec Sheet.
  • CID: Not specified for this item; refer to CoA/Spec Sheet.
• Structural features (general guidance)
  • The detailed 2D/3D structure is not provided in the current listing. If you require functional group information (e.g., heteroaromatic content, HBA/HBD count, ring systems, stereochemistry), please request the Structure/SD file or CoA.
  • For assay planning, obtain the structure to anticipate solubility class (neutral, basic, acidic, zwitterionic) and potential chemical liabilities (e.g., Michael acceptors, redox-active motifs).

Synthetic Utility

This product is intended as a screening compound rather than a general synthetic reagent; no functional group or reactivity information is provided in the listing.

• Item-specific utility
  • Functional groups/reactivity: Not specified for this item; refer to structure/CoA.
• General notes
  • If repurposed as a building block, obtain the structure/SD file to assess reactive handles (e.g., aryl halides for cross-coupling, amines/acids for amide formation).
  • Verify chemical stability under planned conditions (acid/base, heat, oxidants/reductants) before scale-up.
  • When derivatizing a bioactive hit, ensure retention of the pharmacophore and document stereochemistry if applicable.

For synthetic planning, please request the structural data and any available NMR/LC–MS information.

Target Specificity

Target, pathway, and binding data are not provided in this listing.

• Item-specific
  • Primary target/epitope/clone/isotype: Not applicable; this is a small molecule, not an antibody or biologic.
  • Selectivity panel results: Not specified for this item; refer to technical dossier if available.
• General guidance
  • If used as a chemical probe, determine potency (IC50/Ki/EC50), selectivity across related targets, and off-target profiles (e.g., counterscreens, broad panels) before drawing mechanistic conclusions.

Please contact us if you require any known target annotations for ZTA-261.